Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13060MR)

This product GTTS-WQ13060MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13060MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5609MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ12231MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ2679MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ4181MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ6299MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ10609MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ9811MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ13929MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN2477
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW